Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice

Tandem Mass Tags: A Novel Quantification Strategy for Comparative Analysis of Complex Protein Mixtures by MS/MS

Thompson, A., Schäfer, J., Kuhn, K., Kienle, S., Schwarz, J., Schmidt, G., Neumann, T., & Hamon, C. (2003) · Analytical Chemistry · doi:10.1021/ac0262560 · Cited by 2,425

Identification of a Primary Target of Thalidomide Teratogenicity

Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147

Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide

Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

Ebert, B. L., Pretz, J. L., Bosco, J., Chang, C. Y., Tamayo, P., Galili, N., Raza, A., Root, D. E., Attar, E. C., Ellis, S. R., et al. (2008) · Nature · doi:10.1038/nature06494 · Cited by 953

Differential substrate degradation by super-degron: EGFP in wild-type mouse cells, PD-1 requires CRBN humanization

Naruse, C., Ishibashi, O., Ohgushi, M., Imai, H., Matsuzaki, T., Pan, X., Miyazaki, T., Shidahara, Y., Shirakawa, Y., Sugiyama, F., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112992 · Cited by 1

Developmental toxicology profile of the IRAK4 degrader KT-474

Enerson, B. E., Cappon, G. D., Shi, Y., Walther, D. M., Campbell, V., Chen, D., Kuhn, E. W., Massa, V., Ho, C. M. W., Zheng, X., et al. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf170 · Cited by 1

CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation

Minnie, S. A., Ho, K., Boiko, J. R., Adams, R. C., Ensbey, K. S., Nemychenkov, N. S., Legg, S. R. W., Schmidt, C. R., Comstock, M., Lyons, J., et al. (2026) · Blood · doi:10.1182/blood.2025030207 · Cited by 1

Combining lenalidomide with IL-2 family of cytokines enhances activating receptor and perforin/granzyme expression in NK cells

Calescibetta, A. R., Dalton, R., Fortenbery, N. R., Ward, G., Christiansen, S., Chen, X., Cheng, P., Razabdouski, T. N., Glode, A. J., Tu, N., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0344471 · Cited by 1

A dihydrouracil CRBN ligand mitigates IMiD associated safety liabilities in heterobifunctional targeted protein degrader

Rodrigo-Brenni, M. C., Komen, J. C., Hamza, G. M., Bohin, N., Adomavicius, T., Andres, A., Blaho, S., Börjesson, U., Collie, G. W., Donatis, G. M. D., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70663-1 · Cited by 3

Targeting the epigenome and the integrated stress response to normalize colorectal cancer subclonal plasticity and progression

Li, L., Ha, T., Feng, J., DiPrima, M., Wang, D. L., Jailwala, P., Meyer, T. J., Lack, J., Ohnuki, H., & Tosato, G. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08720-2 · Cited by 1

Discovery and Development of First-in-Class Cereblon-Recruiting RIPK1 Degraders

Lu, D., Yu, X., Lin, H., Cheng, R., Zhang, M., Yang, B., Chen, J., Li, F., Qi, X., & Wang, J. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01156 · Cited by 1

How to Transform an Exceptional Case Report Into a Therapy: Following the Frog Out of the Box

Heiblig, M., Alcazer, V., Pleșa, A., Labussière‐Wallet, H., & Sujobert, P. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000629 · Cited by 1

History of IMiDs and Protein Degradation as a Pharmacological Modality

Yamamoto, J., Asatsuma‐Okumura, T., Ito, T., Yamaguchi, Y., & Handa, H. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch8 · Cited by 1

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?

Tesio, M. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000827 · Cited by 1

Mice no longer immune to immunomodulatory drugs

Pichiorri, F. (2018) · Blood · doi:10.1182/blood-2018-08-868083

UbiFast, a rapid and deep-scale ubiquitylation profiling approach for biology and translational researchPreprint

Udeshi, N. D., Mani, D. R., Satpathy, S., Fereshetian, S., Gasser, J. A., Svinkina, T., Ebert, B. L., Mertins, P., & Carr, S. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/785378

New Activities of CELMoDs, Cereblon E3 Ligase-modulating Drugs

Matyskiela, M. E., Clayton, T., Thompson, J. W., Carroll, C. W., Bateman, L. A., LeBrun, L. A., & Chamberlain, P. P. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160691-00094

9052 京都梅津長福寺境内の構成 (1) : 『大梅山長福禅寺全盛古大図』と塔頭の成立時期

伊藤, 毅. (1990) · 学術講演梗概集. F, 都市計画, 建築経済・住宅問題, 建築歴史・意匠

Developing Targeted Therapies for T-cell Acute Lymphoblastic Leukemia

Hu, J. (2022) · doi:10.21007/etd.cghs.2022.0589

Age and Sex Differences in the Eμ-TCL1 Adoptive Transfer Mouse Model of CLL

Sharpe, C., Perry, E., Hertlein, E. K., Muthusamy, N., & Byrd, J. C. (2022) · Blood · doi:10.1182/blood-2022-162900

Data from The IKZF1–IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages

Mougiakakos, D., Bach, C., Böttcher, M., Beier, F., Röhner, L., Stoll, A., Rehli, M., Gebhard, C., Lischer, C., Eberhardt, M., et al. (2023) · doi:10.1158/2326-6066.c.6550200

SMALL-MOLECULE DEGRADERS OF IKAROS ZINC FINGER (IKZF) TRANSCRIPTION FACTORS

Holmberg‐Douglas, N., Shunatona, H. P., Kumi, G. K., & Purandare, A. V. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch10

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

Etxebeste, A. (2023) · Deposito Adademico Digital Universidad De Navarra (University of Navarra) · doi:10.15581/10171/69185

Targeted protein degradation using thalidomide and its derivatives

Yamanaka, S. (2024) · Translational and Regulatory Sciences · doi:10.33611/trs.2024-007

Differential Protein Degradation with a Super-Degron Tag and Thalidomide Analogs: EGFP is Degraded in Wild-Type Mouse Cell, While PD-1 Requires CRBN Humanization, Providing New Insights into T Cell RegulationPreprint

Naruse, C., Ishibashi, O., Ohgushi, M., Imai, H., Matsuzaki, T., Pan, X., Miyazaki, T., Shidahara, Y., Shirakawa, Y., Sugiyama, F., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5084570

Cereblon upregulation overcomes thalidomide resistance in multiple myeloma through mitochondrial functional reprogramming

Marquez, J. C., Park, N., Choi, J. H., Garcia, M. V. F., Flores, J., Nyamaa, B., Seol, J. E., Kim, H. K., Shin, M., Park, S. G., et al. (2025) · BMB Reports · doi:10.5483/bmbrep.2024-0130

TALIDOMIDA E TERATOGENICIDADE: REVISÃO SISTEMÁTICA DE EVIDÊNCIAS MOLECULARES PARA AVALIAÇÃO DE RISCOS NA ASSISTÊNCIA À GESTANTE

Rodrigues, T. D. R., Azevedo, F. H. C., & da Silva, V. G. (2025) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v6i11.7047

Metabolism of new drug modalities research advances – 2025 year in review

Ma, B., Cheruzel, L., Cho, S., Hauri, S., Li, X., Liu, J., Rehm, K., Seneviratne, H. K., Seo, H., Shi, L., et al. (2026) · Drug Metabolism Reviews · doi:10.1080/03602532.2026.2663169

Targeted degradation of CBP/p300 by CBPD-409 exhibits robust anti-myeloma activity

Corradini, S., Maksimos, M., Azab, F., Arsalani, S., Nwarunma, E., Watt, G., Soutar, R. L., Powell, M., Henderson, R., Travers, J., et al. (2026) · Leukemia · doi:10.1038/s41375-026-03004-2

Genetic evidence supports that thalidomide should not be used therapeutically in dogs

Arendt, M. L., & Meadows, J. R. S. (2026) · Veterinary oncology. · doi:10.1186/s44356-026-00067-2

Targeting IKZF2 with molecular glue degraders for cancer immunotherapy

Huang, Y., Huang, S., & Liu, Y. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104820

A patenting perspective of IKZF2 molecular glue degraders (2020-present)

Zhang, X. (2026) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2026.2748593

Improving PROTAC-Mediated Degradation in Mouse Models: BRD9 as a Case Study

Strohmier, B. P., Quarshie, J. T., Raghuvanshi, R., Kaur, S., Conjelko, G. G., & Dykhuizen, E. C. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.6c00628

BindingDB Entry 50020001: Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions.

BindingDB (2024) · UC San Diego · doi:10.7270/q2qc07xx

Targeting MYC through GSPT1 codegradation in blood cancers

Powell, J. A., & Pitson, S. M. (2026) · Blood · doi:10.1182/blood.2026035659

Investigating the Mechanism and Species-Specificity of Thalidomide Derivatives

Fink, E. C. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)

Investigating the Molecular Mechanisms of Action of Lenalidomide and Other Immunomodulatory Derivatives

Haldar, S. D. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)

Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn

Röhner, L., Ng, Y. L. D., Scheffold, A., Lindner, S., Köpff, S., Brandl, A., Beilhack, A., & Krönke, J. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.11.004 · Cited by 5

Another action of a thalidomide derivative

Ito, T., & Handa, H. (2015) · Nature · doi:10.1038/nature14628 · Cited by 15

Lenalidomide induces degradation of

Hurst, S. N., & Ebert, B. L. (2016)